埃维纳库马布在5至17岁的患者中使用,患者患有同卵性家族性高胆固醇血清症
Robert S Rosenson1, Eliot A Brinton2, Daniel Gaudet3
1Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Atherosclerosis
|January 8, 2026
概括
埃维纳巴可显著降低LDL-C在患有同卵性家族高胆固醇血症 (HoFH) 的儿童和青少年. 这种新疗法被证明比标准治疗更有效,为管理这种罕见的遗传疾病提供了新的选择.
科学领域:
- 心血管医学 心血管医学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 同胞性家族性高胆固醇血症 (HoFH) 是一种罕见的遗传性疾病.
- 患有HoFH的儿科患者通常需要密集的降脂疗法 (LLT).
- 现有的治疗方法可能无法充分降低低密度脂蛋白胆固醇 (LDL-C) 水平.
研究的目的:
- 评估埃维纳库马布在小儿HoFH患者的长期疗效.
- 评估埃维纳库马布在患有HoFH的儿童和青少年中的安全性.
- 确定埃维纳库马布对LDL-C和其他脂质参数的影响.
主要方法:
- 第三阶段,单臂,开放标签研究 (NCT04233918,NCT03409744) 招募儿童 (5-11岁) 和青少年 (12-17岁) 患有HoFH.
- 参与者接受了静脉注射埃维纳库马布 (每4周15毫克/千克),同时接受稳定的LLT和经常的脂蛋白非瑞斯.
- 测量结果包括48周和72周LDL-C和其他脂质的变化,以及治疗出现的不良事件 (TEAE) 的评估.
主要成果:
- 埃维纳库马布在儿童和青少年的LDL-C降低了41-45%在第48周和41-51%在第72周.
- 尽管同时优化了LLT和脂蛋白异位,但观察到显著的LDL-C降低.
- 在100%的幼儿和86%的青少年中报告了TEAE;大多数都不被认为与治疗有关.
结论:
- 埃维纳库马布在小儿HoFH患者中显示出显著的LDL-C降低.
- 该疗法有效地作为现有治疗方法的补充,包括脂蛋白非瑞斯.
- 对于需要进一步降低LDL-C的儿科HoFH患者,应考虑使用Evinacumab.
相关概念视频
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Pharmacokinetics in Pediatric Patients: Drug Metabolism
189
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
189
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
433
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433
Myocarditis III: Medical Management
168
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Drug Dosing: Infants and Children
248
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
248


